|
Synonyms: CB-6 | JS-016 | LY-CoV016 | LY3832479
Compound class:
Antibody
Comment: Etesevimab (LY3832479) is a monoclonal antibody against the surface spike protein of SARS-CoV-2. It was developed by Eli Lilly, but such is the speed of COVID-19 therapeutic development, there are no peer-reviewed articles that report its design, preclinical or early clinical data.
|
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 11873 | etesevimab |
| Synonyms |
| CB-6 | JS-016 | LY-CoV016 | LY3832479 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1107 |
| Other databases | |
| GtoPdb PubChem SID | 434321766 |
| Search PubMed clinical trials | etesevimab |
| Search PubMed titles | etesevimab |
| Search PubMed titles/abstracts | etesevimab |
